Varlilumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Varlilumab
Monoclonal antibody
Type ?
Source Human
Target CD27
Clinical data
Synonyms CDX-1127
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
Chemical and physical data
Formula C6486H9992N1740O2022S42
Molar mass 146.0 kg/mol

Varlilumab (CDX-1127) (INN[1]) is a monoclonal antibody designed for immunotherapy for solid tumors and hematologic malignancies.[2]

This drug was developed by Celldex Therapeutics.

Mechanism

It is an anti-CD27 antibody and helps activate T-cells.[3]

Clinical trials

It (in combination with ONT-10) has undergone a phase 1B clinical trial for advanced breast or ovarian cancer.[4]

In combination with anti-PD-1 nivolumab it has undergone a phase 1/2 trial for advanced refractory solid tumours.[5]

References[edit]